HC Wainwright Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price

Apellis Pharmaceuticals (NASDAQ:APLS) had its price objective decreased by analysts at HC Wainwright from $83.00 to $57.00 in a research report issued on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 103.03% from the stock’s previous close.

Several other equities research analysts have also recently issued reports on APLS. Robert W. Baird reduced their price objective on shares of Apellis Pharmaceuticals from $96.00 to $92.00 and set an “outperform” rating on the stock in a research report on Monday, September 23rd. Wedbush raised their price objective on Apellis Pharmaceuticals from $38.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday, August 9th. UBS Group decreased their target price on Apellis Pharmaceuticals from $85.00 to $83.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Jefferies Financial Group reiterated a “buy” rating and set a $80.00 price objective on shares of Apellis Pharmaceuticals in a research report on Wednesday, July 31st. Finally, Evercore ISI upgraded Apellis Pharmaceuticals to a “strong-buy” rating in a report on Thursday, October 31st. Five analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.18.

Apellis Pharmaceuticals Stock Performance

APLS opened at $28.08 on Wednesday. The firm has a market cap of $3.42 billion, a P/E ratio of -10.25 and a beta of 0.87. Apellis Pharmaceuticals has a 1-year low of $24.34 and a 1-year high of $73.80. The company has a 50 day simple moving average of $31.58 and a two-hundred day simple moving average of $37.26. The company has a debt-to-equity ratio of 1.73, a current ratio of 5.08 and a quick ratio of 4.18.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). The business had revenue of $196.83 million for the quarter, compared to the consensus estimate of $200.00 million. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. Apellis Pharmaceuticals’s revenue was up 78.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.17) earnings per share. Equities analysts forecast that Apellis Pharmaceuticals will post -1.4 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director A. Sinclair Dunlop sold 37,000 shares of the company’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $36.23, for a total value of $1,340,510.00. Following the sale, the director now directly owns 100,000 shares of the company’s stock, valued at $3,623,000. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 6.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Wolverine Asset Management LLC purchased a new position in shares of Apellis Pharmaceuticals during the 3rd quarter valued at about $27,000. Capital Performance Advisors LLP acquired a new position in Apellis Pharmaceuticals in the third quarter valued at approximately $56,000. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in Apellis Pharmaceuticals in the 1st quarter worth approximately $89,000. nVerses Capital LLC lifted its stake in shares of Apellis Pharmaceuticals by 300.0% in the 2nd quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock valued at $107,000 after purchasing an additional 2,100 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Apellis Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock worth $130,000 after purchasing an additional 781 shares during the period. 96.29% of the stock is owned by hedge funds and other institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).